Juno Therapeutics, Inc., A Bristol-myers Squibb Company

This early-stage study is testing a new cell therapy called CC-97540 for people with severe autoimmune diseases that haven't responded to multiple treatments. The therapy involves collecting a patient's own immune cells, engineering them to target specific immune cells (B cells),…

This is an early-stage study testing a new type of cell therapy called BMS-986453 in adults with multiple myeloma that has returned or stopped responding to other treatments. The therapy involves modifying a patient's own immune cells to attack the cancer. The main goals are to f…

This early-stage study is testing a new treatment called BMS-986515, which uses immune cells (CAR-T cells) from healthy donors, for people with severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check if the treatment is safe, what sid…

This study is testing a new type of treatment called arlocabtagene autoleucel (BMS-986393), a CAR T-cell therapy, for adults with multiple myeloma that has returned or stopped responding to other treatments. The goal is to see how well this therapy works and how safe it is for pa…

This study is testing whether a new type of personalized immune cell therapy, called arlo-cel, works better than standard treatments for adults with multiple myeloma that has returned or stopped responding to prior therapies, including lenalidomide. Researchers will compare how l…

This study is testing whether a personalized immune cell therapy called liso-cel can effectively treat primary central nervous system lymphoma (a rare brain cancer) as the first treatment for patients who are not eligible for stem cell transplants. The trial will enroll 65 adults…

This study is testing an experimental one-time treatment called CC-97540 for people with active systemic lupus erythematosus (SLE), including lupus affecting the kidneys. The treatment involves collecting and genetically modifying a patient's own immune cells (CAR T-cells) to tar…

This early-stage study is testing whether a modified immune cell therapy called CC-97540 is safe for people with multiple sclerosis or myasthenia gravis. The treatment uses specially engineered T-cells that target CD19, a protein on certain immune cells thought to drive these aut…

This early-stage study is testing a new type of personalized immune cell therapy (called arlocabtagene autoleucel) when given alongside other investigational drugs. It aims to find safe doses and see if these combinations can help control multiple myeloma that has returned or sto…